Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Amazon Web Services to Enhance Services for Healthcare Industry in Japan
June 5, 2019
- Takeda’s Takhzyro Reduces HAE Attacks in Initial Phase of Treatment
June 5, 2019
- No Japanese Enrolled, but AstraZeneca to Discuss Lynparza’s Pancreatic Cancer Data with PMDA: Oncology Chief
June 4, 2019
- Alecensa Slashes Progression Risk by 63% vs. Xalkori in Frontline NSCLC
June 4, 2019
- Lumicef Now in Japan PIII for Systemic Sclerosis: Kyowa Kirin
June 4, 2019
- Alecensa Filed in Japan for Rare Lymphoma: Chugai
June 4, 2019
- Rakuten Medical’s Photoimmunotherapy Demonstrates Favorable Tolerability in PIIa
June 4, 2019
- ASKA to Transfer Menoaid Hot Flash Drug to Hisamitsu
June 4, 2019
- Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
June 4, 2019
- Takeda Pledges 1 Billion Yen in Global Fund, 2nd Investment in Fighting for HIV, TB, and Malaria
June 4, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
- Rakuten Medical Sets Up Outposts in Netherlands, Taiwan
June 3, 2019
- Janssen Japan Files Erleada for Castration-Sensitive Prostate Cancer
June 3, 2019
- Additional OS Data to Be Added to Xospata’s US Label: Astellas
June 3, 2019
- Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
- Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
May 31, 2019
- Novartis, Sumitomo Dainippon to Jointly Promote Equa, EquMet
May 31, 2019
- Teva Takeda Yakuhin Voluntary Recalls Menatetrenone Capsules
May 31, 2019
- Application for Mitsubishi Tanabe’s ALS Drug Pulled in EU
May 31, 2019
- Ono Files Opdivo for Second-Line Treatment of Esophageal Cancer
May 31, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…